The following reports are published by the DMHC and made available to the public.

• Timely Access Report
• Prescription Drug Cost Transparency Report (SB 17)
• Large Group Aggregate Rates and Prescriptions Drug Costs Report
• Individual and Small Group Aggregate Premium Rate Report
• 2022 Health Equity and Quality Recommendations Report

Timely Access Report

The Timely Access Report summarizes provider appointment availability data that health plans submitted to the DMHC. The charts within this report show provider responses to appointment availability requests. 

Measurement Year 2021

• MY 2021 Timely Access Report
• MY 2021 Timely Access Data

Measurement Year 2020

• MY 2020 Timely Access Report
• MY 2020 Timely Access Data

Measurement Year 2019

• MY 2019 Timely Access Report
• MY 2019 Timely Access Data

Measurement Year 2018

• MY 2018 Timely Access Report
• MY 2018 Timely Access Data

Measurement Year 2017

• MY 2017 Timely Access Report
• MY 2017 Timely Access Data

Measurement Year 2016

• MY 2016 Timely Access Report
• MY 2016 Timely Access Data

Measurement Year 2015

• MY 2015 Timely Access Report
• MY 2015 Timely Access Data

Measurement Year 2014

• MY 2014 Timely Access Report
• MY 2014 Timely Access Data

Prescription Drug Cost Transparency Report

Senate Bill (SB) 17 (2017) requires health plans and health insurers that file rate information with the DMHC or the California Department of Insurance (CDI) to annually report specific information related to the costs of covered prescription drugs. This report looks at the impact of the cost of prescription drugs on health plan premiums in the commercial market.

Measurement Year 2021

• 2021 Prescription Drug Cost Transparency Report (SB 17)

Measurement Year 2020

• 2020 Prescription Drug Cost Transparency Report (SB 17)

Measurement Year 2019

• 2019 Prescription Drug Cost Transparency Report (SB 17)

Measurement Year 2018

• 2018 Prescription Drug Cost Transparency Report (SB 17)

Measurement Year 2017

• 2017 Prescription Drug Cost Transparency Report (SB 17)

Large Group Aggregate Rates and Prescription Drug Cost Report

SB 546 (2015) requires health plans to submit aggregate rate information for products in the large group market. In addition, SB 17 (2017) requires health plans to submit specific prescription drug cost information. The report looks at the reasons for changes in the rates, benefits, and cost sharing in the large group market as well as prescription drug costs on health plan premiums.

Measurement Year 2022

• Large Group Aggregate Rates and Prescription Drug Costs Report for Measurement Year 2022

Measurement Year 2021

• Large Group Aggregate Rates and Prescription Drug Costs Report for Measurement Year 2021

Measurement Year 2020

• Large Group Aggregate Rates and Prescription Drug Costs Report for Measurement Year 2020

Measurement Year 2019

• Large Group Aggregate Rates and Prescription Drug Costs Report for Measurement Year 2019

Measurement Year 2018

• Large Group Aggregate Rates and Prescription Drug Costs Report for Measurement Year 2018

Measurement Year 2017

• Large Group Aggregate Rates Report for Measurement Year 2017

Measurement Year 2016

• Large Group Aggregate Rates Report for Measurement Year 2016

 Individual and Small Group Aggregate Premium Rate Report

Assembly Bill (AB) 2118 (Kalra, 2020) requires health plans that offer commercial products in the individual and small group market to report annually to the DMHC specified information, including premiums, enrollment, and trend factors. This report looks at the individual and small group aggregate rate information, benefits, cost sharing and weighted average rate on health premium.

Measurement Year 2022

• Individual and Small Group Aggregate Premium Rate Report Year 2022

Measurement Year 2021

• Individual and Small Group Aggregate Premium Rate Report Year 2021
   

Health Equity and Quality Committee Recommendations Report 

The DMHC convened a Health Equity and Quality Committee to make recommendations to the Department for standard health equity and quality measures, including annual benchmark standards for assessing equity and quality in health care delivery required by Assembly Bill (AB) 133  (2021). This report documents the recommendations developed by the Committee, which met over eight months in a series of public meetings.

• 2022 Health Equity and Quality Committee Recommendations Report